Shares of CymaBay Therapeutics Inc. (NASDAQ:CBAY) have received a consensus recommendation of “Buy” from the eleven analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $13.71.

A number of research firms recently commented on CBAY. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $12.00 price target on shares of CymaBay Therapeutics in a research report on Tuesday, July 25th. Oppenheimer Holdings, Inc. raised their price target on shares of CymaBay Therapeutics from $8.00 to $15.00 and gave the stock an “outperform” rating in a research report on Thursday, July 20th. Citigroup Inc. reissued an “outperform” rating and issued a $15.00 target price (up from $8.00) on shares of CymaBay Therapeutics in a report on Thursday, July 20th. Ifs Securities reissued a “strong-buy” rating on shares of CymaBay Therapeutics in a report on Monday, July 17th. Finally, CIBC reissued an “outperform” rating and issued a $15.00 target price (up from $8.00) on shares of CymaBay Therapeutics in a report on Thursday, July 20th.

Shares of CymaBay Therapeutics (NASDAQ CBAY) opened at 6.10 on Friday. The firm’s market capitalization is $266.91 million. CymaBay Therapeutics has a 12 month low of $1.15 and a 12 month high of $8.29. The stock’s 50 day moving average is $6.80 and its 200 day moving average is $4.94.

CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.06. Equities research analysts forecast that CymaBay Therapeutics will post ($0.80) earnings per share for the current fiscal year.

In other news, insider Sujal Shah bought 10,000 shares of the firm’s stock in a transaction on Thursday, July 20th. The shares were purchased at an average cost of $7.34 per share, with a total value of $73,400.00. Following the acquisition, the insider now directly owns 75,891 shares in the company, valued at $557,039.94. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Charles Mcwherter bought 5,000 shares of the firm’s stock in a transaction on Thursday, July 20th. The stock was purchased at an average cost of $7.43 per share, for a total transaction of $37,150.00. Following the completion of the acquisition, the senior vice president now owns 5,100 shares in the company, valued at $37,893. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 20,000 shares of company stock worth $144,750. Insiders own 15.10% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the business. TFS Capital LLC acquired a new stake in shares of CymaBay Therapeutics in the 1st quarter valued at approximately $169,000. Boxer Capital LLC acquired a new stake in shares of CymaBay Therapeutics in the 1st quarter valued at approximately $3,342,000. ClariVest Asset Management LLC acquired a new stake in shares of CymaBay Therapeutics in the 1st quarter valued at approximately $105,000. Acadian Asset Management LLC acquired a new stake in shares of CymaBay Therapeutics in the 1st quarter valued at approximately $129,000. Finally, LVM Capital Management Ltd. MI boosted its stake in shares of CymaBay Therapeutics by 100.0% in the 2nd quarter. LVM Capital Management Ltd. MI now owns 20,000 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 10,000 shares in the last quarter. 25.80% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/08/cymabay-therapeutics-inc-cbay-receives-average-recommendation-of-buy-from-analysts.html.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Analyst Recommendations for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.